Moreover, TILs were also used to envisage the clinical benefit of anti-PD1 immunotherapy, especially at the invasive margin where they were directly correlated with response to anti-PD-1 immunotherapy and an immunohistochemistry-based assessment of CD8+ T cell density in the core of the tumor [47, 48]. Here, PDCD1 is linked to neoplasm.